The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Yonsei University

Status: Completed

Conditions: Uterine Cancer

Treatments: Drug: Dexmedetomidine group; Drug: Control group

Study type: Interventional

Funder types: Other

Identifiers

NCT02896413

4-2015-0453

Details and patient eligibility

About

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

Enrollment: 100 patients

Sex: Female

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ
• patient scheduled for uterine cancer surgery

Exclusion criteria

• ASA physical status Ⅳ
• severe hepatorenal disease
• infection
• metastasis to other organ
• problem with communication

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

100 participants in 2 patient groups, including a placebo group

Dexmedetomidine Group

Experimental group

Description:

dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery

Treatment:

Drug: Dexmedetomidine group

Control Group

Placebo Comparator group

Description:

0.9% saline infusion

Treatment:

Drug: Control group